Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements.

Front Oncol · 2023 · PMC10319053 · PMID 37409250

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

showed a trendp = 0.10so close (0.05 < p ≤ 0.1)

However, patients with RAS wild-type, right-sided mCRC who received bevacizumab in the first-line setting showed a trend toward longer OS than those who received cetuximab (HR 1.36; 95% CI 0.93–1.99; p = 0.10).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.